SCHEMBL4568465

SCHEMBL4568465

COC(=O)c1cccc(Cc2c(-c3ccc(F)cc3)[nH]c3cc(C)ccc23)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM4 O15151 1/20 0.43
MDM2 Q00987 1/20 0.43
MAPT P10636 3/20 0.40
MAPK13 O15264 1/20 0.39
ALOX5 P09917 1/20 0.39
GCGR P47871 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
CYP19A1 P11511 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
TSPO P30536 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4568098 0.91 MDM4 (0.53) MDM4MDM2MAPTSMN1; SMN2KDM4E
SCHEMBL4568179 0.90 CYP19A1 (0.50) MAPTMAPK13MAPK12MAPK11MAPK14
SCHEMBL3708152 0.89 MDM4 (0.43) MDM4MDM2MAPTCYP19A1SMN1; SMN2
SCHEMBL3703738 0.89 TUBB4A (0.46) MDM4MDM2MAPTCYP19A1PARP1
SCHEMBL4568470 0.88 CXCR2 (0.42) MAPTMAPK13ALOX5GCGRMAPK12
SCHEMBL4568518 0.87 CYP19A1 (0.42) MAPTMAPK13MAPK12MAPK11MAPK14
SCHEMBL4568176 0.87 MDM4 (0.41) MDM4MDM2MAPTCYP19A1KDM4E
SCHEMBL4568473 0.87 TLR9 (0.41) MAPTPARP1
SCHEMBL4568521 0.86 CXCR2 (0.44) MAPTMAPK13ALOX5GCGRMAPK12
SCHEMBL15998678 0.85 MDM4 (0.40) MDM4MDM2MAPTMAPK14SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF PTGER1, CYSLTR1, LTB4R MDM4 4719/4885MDM2 2739/4885MAPT 3199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.